BLAINJECTIONINJECTABLE
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
AVSOLA (infliximab-axxq) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2019.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVSOLA (infliximab-axxq) is a monoclonal antibody biosimilar developed by Amgen that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is indicated for TNF-mediated inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. The drug works by binding to TNF receptors and inhibiting the inflammatory cascade, providing disease-modifying activity in autoimmune and inflammatory disorders.
$0.003BPart D
PeakProduct is at peak lifecycle stage with modest Part D penetration ($3M, 1,014 claims in 2023), suggesting commercial team is focused on payer negotiation and market expansion within a competitive biosimilar space.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
The 89 linked positions reflect strong demand across commercial, data science, and regulatory functions as Amgen manages AVSOLA's market access and competitive positioning in a crowded TNF-inhibitor class. Working on AVSOLA provides visibility into biosimilar commercialization, health economics, payer negotiation, and comparative positioning—critical skills in the biologic/biosimilar era.
Oncology Specialist
Worked on AVSOLA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.